Vaccination with genetically engineered allergens prevents progression of allergic disease
Vaccination with genetically engineered allergens prevents progression of allergic disease
复制标题
DOI：
10.1073/pnas.0404735101
复制
发表时间：
2004-10-05
影响因子：
11.1
通讯作者：
Valenta, R
中科院分区：
文献类型：
--
作者：
Niederberger, V;Horak, F;Valenta, R
IgE介导的变态反应影响工业化国家中>25%的人口。反复接触诱发疾病的过敏原会导致过敏原特异性IgE抗体升高，并导致疾病进展为更严重的表现。我们的研究使用一种基于转基因过敏原衍生物的疫苗来治疗过敏患者。我们通过基因工程开发了主要桦树花粉过敏原Bet v 1的低过敏性衍生物，并在一项双盲、安慰剂对照研究中为桦树花粉过敏患者（n = 124）接种了疫苗。积极治疗诱导保护性IgG抗体，抑制过敏原诱导的炎症介质的释放。我们还观察到积极治疗的患者皮肤敏感性降低以及症状改善。最重要的是，季节性桦树花粉暴露引起的过敏原特异性IgE的升高在接种疫苗的患者中显着降低。用基因工程过敏原衍生物接种疫苗是一种治疗过敏的方法，不仅可以改善过敏反应，还可以减少疾病背后的IgE产生。
IgE-mediated allergy affects >25% of the population in industrialized countries. Repeated contact with the disease-eliciting allergens induces rises of allergen-specific IgE Abs and progression of the disease to more severe manifestations. Our study uses a type of vaccine that is based on genetically modified allergen derivatives to treat allergic patients. We developed hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, by genetic engineering and vaccinated birch pollen-allergic patients (n = 124) in a double-blind, placebo-controlled study. Active treatment induced protective IgG Abs that inhibited allergen-induced release of inflammatory mediators. We also observed a reduction of cutaneous sensitivity as well as an improvement of symptoms in actively treated patients. Most important, rises of allergen-specific IgE induced by seasonal birch pollen exposure were significantly reduced in vaccinated patients. Vaccination with genetically engineered allergen derivatives is a therapy for allergy that not only ameliorates allergic reactions but also reduces the IgE production underlying the disease.